Description
The opportunity involves the supply of Ibuprofen 400MG/600MG/800MG tablets. The contract has been awarded to Exelan Pharmaceuticals Inc. The contract is being modified to exercise Option Year 1, effective from February 12, 2025, through February 11, 2026. All other terms and conditions remain unchanged. The scope of work includes the delivery of the specified tablets. Key aspects to consider for this opportunity include the contract duration, the type of tablets to be supplied, and the terms and conditions of the contract.
• The contract duration is for 1 year, from February 12, 2025, to February 11, 2026.
• The tablets to be supplied are Ibuprofen 400MG/600MG/800MG.
• The terms and conditions of the contract remain largely unchanged, with the exception of the exercised option year.